122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

Abstract Background With the significant improvement of the cure rate and survival rate of cancer patients, the survivors need to face quality of life problems, such as significant decline in reproductive system development, ovarian reserves and function, and even fertility loss and early menopause. These problems are often highly associated with chemotherapy-induced ovarian damage in the course of cancer treatment. However, there are no ideal treatment strategies at present. In our attempt to develop reagents and approaches for delaying ovarian aging and protecting chemotherapy-induced ovarian injury, we recently found that metformin may be the most potential drug to protect female malignant tumor patients from chemotherapy-induced ovarian injury. The optional trial is aimed to test whether administration of metformin during chemotherapy could protect normal ovarian function of early breast cancer patients. Methods This study is prospective, randomized, double-blind and placebo-controlled. Female early breast cancer patients (N=314), were randomly assigned to two groups (placebo, metformin 2000 mg). Metformin was administered during and after chemotherapy for patients with stage I-IIIa breast cancer. The primary outcome was the menstruation recovery rate 12 months after chemotherapy, defined as recovery of menstruation twice in a row within 1 year. Patients were followed up for 5 years to observe long-term ovarian function and prognosis of tumor, such as overall survival (OS), objective response rate (ORR), disease-free survival (DFS). Quality of life and safety will also be assessed. Discussion Our research will provide new treatment strategy of fertility protection, and clinical treatment guidance for cancer patients.

Download Full-text

Research on the Relationship Between Self-Management Efficacy and Quality of Life for Breast Cancer Patients Receiving Endocrine Therapy

10.21203/rs.3.rs-1126991/v1 ◽

2022 ◽

Author(s):

Hongjie Yi ◽

Haoran Jiang ◽

Aiping Wang ◽

Wei Zong ◽

Yu Dong ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Cancer Patients ◽

Endocrine Therapy ◽

Influencing Factors ◽

The Self ◽

Self Management ◽

Breast Cancer Patients ◽

The Relationship

Abstract Purpose To investigate the status quo and relationship between self-management efficacy and quality of life (QOL) of patients with breast cancer undergoing endocrine therapy, and to explore the influencing factors of QOL. Methods The convenience sampling method was used to select 240 patients who received endocrine therapy after breast cancer surgery in the First Hospital of China Medical University, the self-designed general data questionnaire, self-management efficacy questionnaire for breast cancer patients with endocrine therapy and quality of life scale for breast cancer patients were used to investigate. The frequency, percentage, mean ± standard deviation were used to describe patients' self-management efficacy and quality of life. Pearson correlation analysis was used to analyze the relationship between self-management efficacy and quality of life, and univariate analysis and multiple stepwise regression were used to analyze the influencing factors of QOL. Results The scores of self-management efficacy and QOL of patients with breast cancer endocrine therapy were 125.21 ± 25.57 and 153.33 ± 19.31 respectively, which were at the middle level; self-management efficacy was significantly positively correlated with quality of life ( p < 0.01 ) ; multiple stepwise regression results showed that self-management efficacy, the number of physical symptoms, monthly family income and recurrence and metastasis were the influencing factors of QOL. Conclusion The self-management efficacy of endocrine therapy was positively correlated with QOL in breast cancer patients. The higher the self-management efficacy of endocrine therapy, the better QOL in breast cancer patients. Self-management efficacy is the main factor affecting the quality of life of breast cancer patients undergoing endocrine therapy. Improving the level of self-management efficacy can improve their quality of life.

Download Full-text